Binding affinity of different commercial FIX therapies to collagen IV

Project Description

Haemophilia B is a blood clotting disorder caused by deficiency of blood coagulation Factor IX (FIX), resulting in bruising and bleeding. Haemophilia B affects 1:30,000 males in the UK and is treated by infusion of FIX concentrate to sustain normal function of the blood clotting process. There are several preparations of FIX available to patients; standard concentrates which must be administered 2-3 times weekly (BeneFIX, Rixubis) and long-acting concentrates containing modified FIX molecules which require once weekly infusion (Alprolix, Idelvion, Refixia). Collagen IV is a structural protein that is present in the blood vessel wall that is exposed during injury (such as joint bleeds in haemophilia). Our preliminary data has also shown that the different FIX preparations have different blood clotting profiles when in complex with collagen IV. The aim of this study is to elucidate the binding interaction between the different FIX preparations and collagen IV. This will provide key information on the optimum therapy for Haemophilia B patients.